Risk of immune-related colitis with PD-1/PD-L1 inhibitors vs chemotherapy in solid tumors: systems assessment

@article{Su2018RiskOI,
  title={Risk of immune-related colitis with PD-1/PD-L1 inhibitors vs chemotherapy in solid tumors: systems assessment},
  author={Q. Su and Xiao-Chen Zhang and Xinhua Shen and Yan-Li Hou and Zhigang Sun and Zu-Hua Gao},
  journal={Journal of Cancer},
  year={2018},
  volume={9},
  pages={1614 - 1622}
}
Background: We performed a meta-analysis to evaluate the risk of immune-related colitis associated with PD1/PD-L1 inhibitors as compared to chemotherapy in solid tumor patients. Methods: Eligible studies were identified through a comprehensive search of multiple databases and included solid tumor patients in randomized controlled trials (RCTs) with PD-1/PD-L1 inhibitors. The data was analyzed by Stata version 12.0 software. Results: After exclusion of ineligible studies, 11 clinical trials were… Expand
CD103+ tumor-infiltrating lymphocytes predict favorable prognosis in patients with esophageal squamous cell carcinoma
...
1
2
...

References

SHOWING 1-10 OF 39 REFERENCES
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities
Review: Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
...
1
2
3
4
...